Previous 10 | Next 10 |
Gainers: Pasithea Therapeutics (NASDAQ:KTTA) +257%, Petros Pharmaceuticals (NASDAQ:PTPI) +73%, Gracell Biotechnologies (NASDAQ:GRCL) +64%, iSpecimen (NASDAQ:ISPC) +43%, Qualigen Therapeutics (NASDAQ:QLGN) +33%. Losers: Longeveron (NASDAQ:LGVN) -36%...
The obesity epidemic is still bursting at the seams. In fact, according to Medical News Today, the issue contributes to more than five million global deaths every year. In addition, a ccording to the World Health Organization, obesity has tripled since 1975. More than 1.9 billion adults...
Penny stocks are one of the quickest ways to make money in the stock market. Whether you’re day trading, swing trading, or even investing, these cheap names can offer the potential for significant gains. On an almost daily basis, we see various companies attract the attention of ...
Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market. The pandemic is predicted to have a long and short term im...
Pasithea Therapeutics (NASDAQ:KTTA) +172% adds Esketamine nasal spray to its clinic offerings in the U.K. Petros Pharmaceuticals (NASDAQ:PTPI) +99%. iSpecimen ISPC +99% is set to extend rally after contract win for COVID-19 research Qualigen Therapeutics (NASDAQ:QLGN) +72%. Aad...
Pasithea Therapeutics (NASDAQ:KTTA) soars 132% premarket after announcing that its wholly owned subsidiary, Pasithea Clinics, has been approved to provide esketamine nasal spray (Spravato) for treatment-resistant depression in adults, and has begun offering the treatment in its Knig...
MIAMI BEACH, Fla., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological dis...
Dicerna Pharmaceuticals DRNA +78% Novo Nordisk agrees to acquire Dicerna for more than $3 billion Cardiff Oncology (NASDAQ:CRDF) +23% announces $15M equity investment from Pfizer through its Pfizer breakthrough growth initiative Cloopen Group Holding RAAS +19% on Q3 result...
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion therapy for the treatment of mental health disorders and t...
Progenity PROG +20% amid social media buzz Canoo (NASDAQ:GOEV) +17%. Camber Energy (NYSE:CEI) +17%. Asia Pacific Wire & Cable APWC +14% on 1H results SPI Energy (NASDAQ:SPI) +13%. Ensysce Biosciences (NASDAQ:ENSC) +11%. Mullen Automotive (NASDAQ:MULN) +10%. Vir Biotechnolog...
News, Short Squeeze, Breakout and More Instantly...
Pasithea Therapeutics Corp. Company Name:
KTTA Stock Symbol:
NASDAQ Market:
Pasithea Therapeutics Corp. Website:
MIAMI, June 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis typ...
-- PAS-004 inhibition of in vitro NRAS cell lines does not plateau in contrast to approved MEK inhibitors -- -- PAS-004 inhibition of in vitro NRAS cell lines is greater than selumetinib and binimetinib and similar to trametinib -- -- PAS-004 shows superior activity versus selumetinib and...